Clinical trial · Observational
Discovering New Genetic Markers in Adults and Children Who May Be At Risk for Hereditary Forms of Cancer
Discovery and Characterization of Susceptibility Genes in Adults and Children With Suspected Hereditary Cancer Predisposition
NCT03922893CI-TRIAL-00098922recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to attempt to identify genetic mutations or other gene-based variations in adults and children who have cancer, or are likely to develop an inherited form of cancer, and potentially reduce their risk for cancer or treat the cancer earlier.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood | Genetic | — | UNRESOLVED |
| Family History Information | Other | — | UNRESOLVED |
| ORAGENE | Genetic | — | UNRESOLVED |
| Skin Biopsy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Proband
- description
- First individual in a family to consent to this protocol
- interventionNames
- Other: Family History Information
- Genetic: ORAGENE
- Genetic: Blood
- Other: Skin Biopsy
- label
- Family Member Participants
- description
- Family members of the proband will be approached to consent to this protocol
- interventionNames
- Other: Family History Information
- Genetic: ORAGENE
- Genetic: Blood
- Other: Skin Biopsy
Primary outcomes (1)
- measure
- Discovery of novel cancer susceptibility genes
- timeFrame
- Up to 10 years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Individuals who have undergone clinical and/or research genetic evaluation, found to have or not have a germline genetic variant (pathogenic, likely pathogenic, variant of uncertain/unknown significance, likely benign). * Individuals with or without a personal history of malignant or pre-malignant lesions who demonstrate: a) clinical findings suggestive of a genetic cancer susceptibility syndrome including very early age at onset, multiple primary malignancies, or other features; and/or b) family histories suggestive of a genetic cancer susceptibility syndrome, or c) other features suggesting inherited etiology of malignancy as determined by the PI. * Family members of the above participants. Both children (with parental consent as age appropriate) and adults are eligible to participation. * Individuals may or may not be enrolled MSK patients; probands may be referred to (or self-referred to) the study and may be enrolled at discretion of the PI and if able to provide informed consent. * Biospecimens derived from deceased family members may be used for research in this study if consent if provided by the executor of the estate of that individual. Exclusion Criteria: * Patients will be excluded from this study if he/she has physical, cognitive or psychiatric conditions that interfere with ability to give meaningful informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.